Grades III to IV toxicities by CTC
. | Mean nos. of adverse events per patient . | . | . | Cumulative incidences . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Category . | Nonablative (n = 60) . | Ablative (n = 74) . | P . | Nonablative patients, % (n = 60) . | Ablative patients, % (n = 74) . | P . | ||||
Hematologic | 3.5 | 4.9 | < .0001 | 100 | 100 | .99 | ||||
Cardiovascular | 0.9 | 1.1 | 0.4 | 68 | 80 | .1 | ||||
Gastrointestinal | 0.6 | 1.7 | < .0001 | 27 | 80 | < .0001 | ||||
Hemorrhage | 0.3 | 0.6 | .02 | 13 | 34 | .005 | ||||
Hepatic | 0.7 | 1.2 | .005 | 48 | 68 | .02 | ||||
Infection | 1.6 | 2.2 | .02 | 77 | 88 | .09 | ||||
Metabolism | 1.6 | 1.8 | .3 | 72 | 87 | .03 | ||||
Neurologic | 0.6 | 0.5 | .8 | 23 | 37 | .1 | ||||
Pulmonary | 0.2 | 0.3 | .6 | 12 | 18 | .4 | ||||
Renal | 0.1 | 0.2 | .1 | 7 | 15 | .1 |
. | Mean nos. of adverse events per patient . | . | . | Cumulative incidences . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Category . | Nonablative (n = 60) . | Ablative (n = 74) . | P . | Nonablative patients, % (n = 60) . | Ablative patients, % (n = 74) . | P . | ||||
Hematologic | 3.5 | 4.9 | < .0001 | 100 | 100 | .99 | ||||
Cardiovascular | 0.9 | 1.1 | 0.4 | 68 | 80 | .1 | ||||
Gastrointestinal | 0.6 | 1.7 | < .0001 | 27 | 80 | < .0001 | ||||
Hemorrhage | 0.3 | 0.6 | .02 | 13 | 34 | .005 | ||||
Hepatic | 0.7 | 1.2 | .005 | 48 | 68 | .02 | ||||
Infection | 1.6 | 2.2 | .02 | 77 | 88 | .09 | ||||
Metabolism | 1.6 | 1.8 | .3 | 72 | 87 | .03 | ||||
Neurologic | 0.6 | 0.5 | .8 | 23 | 37 | .1 | ||||
Pulmonary | 0.2 | 0.3 | .6 | 12 | 18 | .4 | ||||
Renal | 0.1 | 0.2 | .1 | 7 | 15 | .1 |